Suven Life Sciences has received four product patents from different countries for its new chemical entities (NCEs) which could be used in treating various central nervous system disorders. he four product patents, one from New Zealand, one from Australia, one from Korea and one from Europe are valid through 2025. With these new patents, the company now has eight patents from Europe, ten from New Zealand, nine from Australia and three from Korea for the NCEs
The company has received the approval for molecules which could be used in the treatment of CNS disorders like Parkinsons, Alzheimers and schizophrenia. Products out of these inventions may be out-licensed at various phases of clinical research like at phase I or phase II
